题名

晚期大腸直腸癌化療副作用之中醫治療回顧性文獻探討及臨床觀察

并列篇名

Traditional Chinese Medicine Treatments on Side Effects of Chemotherapy for Advanced Colorectal Cancer: Literature Review and Clinical Observation

DOI

10.6516/TJTCM.201903_22(1).0008

作者

黃靖鈞(Ching-Chun Huang)；陳忠淵(Jhong-Yuan Chen)

关键词

大腸直腸癌 ； 化療副作用 ； 中醫治療 ； 文獻回顧 ； Advanced colorectal cancer chemotherapy ； Side effects of chemotherapy TCM treatment ； literature review

期刊名称

中醫藥研究論叢

卷期/出版年月

22卷1期（2019 / 03 / 30）

页次

91 - 109

内容语文

繁體中文
中文摘要

大腸直腸癌多年來一直高居台灣癌症死亡率前三名，近年來治療大腸直腸癌有許多進展，合併使用5-fluororuracil（5-FU）及oxaliplatin或irinotecan使得存活率增加，但化學治療的副作用仍是無法避免，而且因為劑量的累積和治療時間的拉長，副作用影響層面只會越來越廣，若我們可以先期掌握目前大腸直腸癌主流的化療方式與其副作用之特性，從中醫藥的角度解釋副作用產生的原因，結合臨床研究的文獻與我們的臨床的觀察分析，進一步討論化療藥物的寒熱偏性，以先期掌握每位大腸癌患者的化療常見副作用並能夠更準確地介入對應治療。針對回顧性文獻主要從四點論述：第一點討論晚期大腸直腸癌之化學治療發展。第二點比較FOLFOX（FOLinic acid, 5-FU, OXaliplatin）和FOLFIRI（FOLinic acid, 5-FU, IRInotecan）兩種化療模式異同。第三點和第四點我們分別探討oxaliplatin的神經毒性和irinotecan的腹瀉副作用，與其中醫治療的概念及臨床研究。最後討論本院臨床觀察到的大腸癌患者化療副作用特性，並嘗試歸納其寒熱證型，分析化療藥物屬性，進一步利用寒者熱之，熱者寒之概念給予治療，期望藉此模式未來可以提升中醫改善各種化療副作用的準確性，強化中西醫結合的價值。
英文摘要

Colorectal cancer is the third leading cause of Taiwan malignancy death for many years. In recent years, there is a lot of progress in the treatment of colorectal cancer. Combination therapy of 5-fluororuracil (5-FU) and oxaliplatin or irinotecan increased survival rate of colorectal cancer patient. However, the side effects of chemotherapy are still unavoidable, and because of the cumulative dose of chemotherapeutic agents and the duration of treatment, the side effects will become more and more extensive. If we can understand the current mainstream chemotherapy of colorectal cancer as well as the characteristics of side effects, explain the causes of side effects by the perspective of Traditional Chinese Medicine (TCM), review the clinical research literature, combine our clinical observations to differentiation of cold and heat syndrome, and presume the cold and heat properties of chemotherapeutic agents in order to predict the side effects of chemotherapy in each patient, and intervene the TCM treatment more accurately after chemotherapy. The discussion of this retrospective literature can be divided into four parts. First, we discuss the development of chemotherapy for advanced colorectal cancer. Second, we compare the similarities and differences between FOLFOX (FOLinic acid, 5-FU, OXaliplatin) and FOLFIRI (FOLinic acid, 5-FU, IRInotecan). Third and fourth, we respectively discuss the neurotoxicity of oxaliplatin, the diarrhea side effects of irinotecan, and related clinical study of TCM. Finally, we discuss the side effects of chemotherapy in patients with colorectal cancer by our clinical observation, summarize the cold and heat syndrome of the side effects from chemotherapy, analyze the characteristics of chemotherapeutic agents, and then use the concept of TCM that the 'cold' syndrome should be treated with medications of 'warm or hot' nature, and vice versa to relieve the side effects of chemotherapy. We hope that this model can improve the accuracy of TCM treatment for relieving various side effects of chemotherapy and strengthen the value of integration of traditional and western medicine.
主题分类 醫藥衛生 > 中醫藥學
醫藥衛生 > 藥理醫學
参考文献
  1. 唐佑任,戴承杰(2015)。中醫藥介入化療藥物副作用的可行性探討。中醫藥論文叢，18(1)，105-120。
    連結：
  2. （漢）張仲景(2005).傷寒論.北京:人民衛生出版社.
  3. Alimonti, A,Gelibter, A,Pavese, I,Satta, F,Cognetti, F,Ferretti, G,Rasio, D,Vecchione, A,Di Palma, M(2004).New approaches to prevent intestinal toxicity of irinotecan-based regimens.Cancer Treat Rev,30(6),555-562.
  4. André, T,Boni, C,Mounedji-Boudiaf, L,Navarro, M,Tabernero, J,Hickish, T,Topham, C,Zaninelli, M,Clingan, P,Bridgewater, J,Tabah-Fisch, I,de Gramont, A(2004).Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.N Engl J Med,350,2343-2351.
  5. Colucci, G,Gebbia, V,Paoletti, G,Giuliani, F,Caruso, M,Gebbia, N,Cartenì, G,Agostara, B,Pezzella, G,Manzione, L,Borsellino, N,Misino, A,Romito, S,Durini, E,Cordio, S,Di Seri, M,Lopez, M,Maiello, E,Montemurro, S,Cramarossa, A,Lorusso, V,Di Bisceglie, M,Chiarenza, M,Valerio, MR,Guida, T,Leonardi, V,Pisconti, S,Rosati, G,Carrozza, F,Nettis, G,Valdesi, M,Filippelli, G,Fortunato, S,Mancarella, S,Brunetti, C,Gruppo Oncologico Dell'Italia Meridionale(2005).Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale.J Clin Oncol.,23,4866-4875.
  6. de Gramont, A,Figer, A,Seymour, M,Homerin, M,Hmissi, A,Cassidy, J,Boni, C,Cortes-Funes, H,Cervantes, A,Freyer, G,Papamichael, D,Le Bail, N,Louvet, C,Hendler, D,de Braud, F,Wilson, C,Morvan, F,Bonetti, A(2000).Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol,18,2938-2947.
  7. Douillard, JY,Cunningham, D,Roth, AD,Navarro, M,James, RD,Karasek, P,Jandik, P,Iveson, T,Carmichael, J,Alakl, M,Gruia, G,Awad, L,Rougier, P(2000).Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.Lancet,355,1041-1047.
  8. Eng, C(2010).Are herbal medicines ripe for the cancer clinic.Sci Transl Med,2(45),41-45.
  9. Farrell, MP,Kummar, S(2003).Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.Clin Colorectal Cancer,2(4),253-256.
  10. Hibi, S、Ina, K、Furuta, R、Kataoka, T、Kojima, S、Kawai, M(2009)。Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer。Gan To Kagaku Ryoho，36(9)，1485-1488。
  11. Hung, MC,Lai, WW,Chen, HHW,Su, WC,Wang, JD(2015).Comparison of expected health impacts for major cancers: integration of incidence rate and loss of quality-adjusted life expectancy.Cancer Epidemiol,39,126-132.
  12. Keefe, DM,Elting, LS,Nguyen, HT,Grunberg, SM,Aprile, G,Bonaventura, A,Selva-Nayagam, S,Barsevick, A,Koczwara, B,Sonis, ST(2014).Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.Cancer Chemother Pharmacol.,74(4),675-680.
  13. Khan, N,Tamboli, E, T,Sharma, V, K,Kumar, S(2013).Phytochemical and pharmacological aspects of Nothapodytes nimmoniana. An overview.Herba polonica,59(1),53-66.
  14. Kummar, S,Copur, MS,Rose, M,Wadler, S,Stephenson, J,O'Rourke, M,Brenckman, W,Tilton, R,Liu, SH,Jiang, Z,Su, T,Cheng, YC,Chu, E(2011).A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan based chemotherapy in patients with advanced colorectal cancer.Clin Colorectal Cancer,10(2),85-96.
  15. Kuriyama, Akira,Endo, Koji(2018).Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.Supportive Care in Cancer,26(4),1051-1059.
  16. Lai, L,Liu, J,Zhai, D,Lin, Q,He, L,Dong, Y,Zhang, J,Lu, B,Chen, Y,Yi, Z,Liu, M(2012).Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor- 2.British journal of pharmacology,165(4b),1084-1096.
  17. Lam, W,Bussom, S,Guan, F,Jiang, Z,Zhang, W,Gullen, EA,Liu, SH,Cheng, YC(2010).The four- herb Chinese medicine PHY906 reduces chemotherapy induced gastrointestinal toxicity.Sci Transl Med.,2(45),45-59.
  18. Lam, W,Liu, SH,Jiang, Z,Cheng, YC(2015).Lessons from the development of the traditional Chinese medicine formula PHY906.Science,347(6219 suppl),S43-S45.
  19. Lehky, TJ,Leonard, GD,Wilson, RH,Grem, JL,Floeter, MK(2004).Oxaliplatin induced neurotoxicity: Acute hyperexcitability and chronic neuropathy.Muscle Nerve,29(3),387-392.
  20. Lin, HH,Chang, YY,Lin, JK,Jiang, JK,Lin, CC,Lan, YT,Yang, SH,Wang, HS,Chen, WS,Lin, TC,Chang, SC(2014).The role of adjuvant chemotherapy in stage II colorectal cancer patients.Int J Colorectal Dis,29(10),1237-1243.
  21. Liu, SH,Cheng, YC(2012).Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy.J Ethnopharmacolo,140(3),614-623.
  22. Mitry, E,Tournigand, C,Andre, T,Douillard, JYY,Louvet, C,Cunningham, D,Magherini, E,Mery-Mignard, D,de Gramont, A,Rougier, P(2004).Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer: a pooled analysis of 254 patients included in 2 randomised trials. ASCO annual meeting proceedings (post-meeting edition).J Clin Oncol,22(suppl),3576.
  23. Mori, K,Kondo, T,Kamiyama, Y,Kano, Y,Tominaga, K(2003).Preventive effect of Kampo medicine (Hange-shashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.Cancer Chemother Pharmacol,51(5),403-406.
  24. Nakamura, M,Komatsu, Y,Muranaka, T,Yagisawa, M,Kawamoto, Y,Nakatsumi, H,Yuki, S,Saiki, T,Ishiguro, A,Tateyama, M,Kobayashi, Y,Miyagishima, T,Takahata, T,Sato, A,Dazai, M,Okuda, H,Fujikawa, K,Eto, K,Muto, S,Hatanaka, K,Amano, T,Sakata, Y(2018).HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment.Annals of Oncology,29(5),226.
  25. Nishioka, M,Shimada, M,Kurita, N,Iwata, T,Morimoto, S,Yoshikawa, K,Higashijima, J,Miyatani, T,Kono, T(2011).The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.Int J Clin Oncol,16(4),322-327.
  26. Oki, E,Emi, Y,Kojima, H,Higashijima, J,Kato, T,Miyake, Y,Kon, M,Ogata, Y,Takahashi, K,Ishida, H,Saeki, H,Sakaguchi, Y,Yamanaka, T,Kono, T,Tomita, N,Baba, H,Shirabe, K,Kakeji, Y,Maehara, Y(2015).Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.Int J Clin Oncol,20(4),767-775.
  27. Reddy, GK,Gibson, AD,Price, N(2005).Evolution of FOLFOX regimens in the treatment of advanced colorectal cancer.Clin Colorectal Cancer,4,296-299.
  28. Rosenoff, SH,Gabrail, NY,Conklin, R,Hohneker, JA,Berg, WJ,Warsi, G,Maloney, J,Benedetto, JJ,Miles, EA,Zhu, W,Anthony, L(2006).A multicenter, randomized trial of long-acting octreotidefor theoptimumprevention of chemotherapy-induced diarrhea: results of the stop trial.J Support Oncol,4(6),289-294.
  29. Saif, MW,Li, J,Lamb, L,Kaley, K,Elligers, K,Jiang, Z,Bussom, S,Liu, SH,Cheng, YC(2014).First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Cancer Chemother Pharmacol,73(2),373-380.
  30. Takasuna, K,Hagiwara, T,Watanabe, K,Onose, S,Yoshida, S,Kumazawa, E,Nagai, E,Kamataki, T.(2006).Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11) -induced delayed diarrhea.Cancer Chemother Pharmacol,25,1-10.
  31. Tournigand, C,André, T,Achille, E,Lledo, G,Flesh, M,Mery-Mignard, D,Quinaux, E,Couteau, C,Buyse, M,Ganem, G,Landi, B,Colin, P,Louvet, C,de Gramont, A(2004).FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.J Clin Oncol,22,229-237.
  32. Uno, T,Ohsawa, I,Tokudome, M,Sato, Y(2005).Effects of Goshajinkigan on insulin resistance in patients with type 2 diabetes.Diabetes Res Clin Pract,69(2),129-135.
  33. Urushiyama, H,Jo, T,Yasunaga, H,Michihata, N,Yamana, H,Matsui, H,Hasegawa, W,Hiraishi, Y,Mitani, A,Fushimi, K,Nagase, T,Yamauchi, Y(2018).Effect of Hangeshashin-To (Japanese Herbal Medicine Tj-14) on Tolerability of Irinotecan: Propensity Score and Instrumental Variable Analyses.Journal of Clinical Medicine,7(9),246.
  34. Wei, Y,Yang, Q,Zhang, Y,Zhao, T,Liu, X,Zhong, J,Ma, J,Chen, YX,Zhao, C,Li, J(2017).Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.Oncotarget,8(9),15230-15241.
  35. Wilson, RH,Lehky, T,Thomas, RR,Quimm, MG,Floeter, MK,Grem, JL(2002).Acute oxaliplatin induced peripheral nerve hyperexcitability.J Clin Oncol,20(7),1767-1774.
  36. Yamamoto, T,Murai, T,Ueda, M,Katsuura, M,Oishi, M,Miwa, Y,Okamoto, Y,Uejima, E,Taguchi, T,Noguchi, S,Kurokawa, N(2009).Clinical features of paclitaxel-induced peripheral neuropathy and role of Gosyajinkigan.Gan To Kagaku Ryoho,36(1),89-92.
  37. Yen, Y,So, S,Rose, M,Saif, MW,Chu, E,Liu, SH,Foo, A,Jiang, Z,Su, T,Cheng, YC(2009).Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma.Anticancer Res,29(10),4083-4092.
  38. 于洋,李曉松,武冰,姚芳芳,張歡歡,李素那,錢麗旗(2015)。加味黃芩湯預防晚期腸癌患者伊立替康化療所致遲發性腹瀉療效觀察。北京中醫藥，34(6)，427-429。
  39. 弓曉霞(2005)。補陽還五湯預防奧沙利鉑外周神經毒性的臨床觀察。河南中醫，25(11)，68-68。
  40. 王浩,朱瑩杰(2015)。中醫藥防治奧沙利鉑所致周圍神經毒性研究進展。解放軍醫藥雜誌，27(4)，76-80。
  41. 王燕萍,沈明謙(2004)。當歸四逆湯藥理研究及臨床應用新進展。廣州醫學院學報，30(5)，31-33。
  42. 田明敏(2018)。黃煌運用黃芩湯、五苓散治療肝癌腹水臨床經驗。上海中醫藥雜誌，52(4)，32-34。
  43. 田楨(2012)。北京中醫藥大學。
  44. 石關桐,李義凱,石印玉(1996)。補陽還五湯對鉗傷大鼠坐骨神經軸漿運輸的影響。中國骨傷，9(1)，3-4。
  45. 吳海良,田靜(2008)。當歸四逆湯加味聯合鈣鎂合劑預防奧沙利鉑神經毒性的臨床觀察。腫瘤基礎與臨床，21(2)，162-163。
  46. 李奕璇(2018)。中藥單體白花丹通過調控VEGF/VEGFR2 信號通路抑制結腸癌血管生成的實驗研究。實用藥物與臨床，7(6)，745-749。
  47. 李道明,王蓉,謝菁(2014)。黃芪桂枝五物湯治療奧沙利鉑化療後周圍神經毒性24例。南京中醫藥大學學報，30(2)，186-188。
  48. 沈瑞池,吳美芳,何恩銘,陳德林,王傑,何建章,周爽(2016)。青脆枝化學成分及其活性研究進展。亞熱帶植物科學，45(04)，379-385。
  49. 肖軍,田靜,閆磊(2016)。加味連理湯預防伊立替康致大腸癌患者遲發性腹瀉臨床研究。山東中醫雜誌，35(12)，1042-1047。
  50. 孟林鳳(2018)。北京中醫藥大學。
  51. 林玉萍(2014)。結腸直腸癌的藥物治療。藥學雜誌，30(3)，86-91。
  52. 林為沁,林志昇,呂建(2015)。Oxaliplatin合併鈣和鎂鹽之實證討論。藥學雜誌，31(1)，43-48。
  53. 邱年永,張光雄(1998).原色臺灣藥用植物圖鑑 5.台北:南天書局出版社.
  54. 胡文雷(2007)。加味補陽還五湯預防治療奧沙利鉑所致神經毒性 57 例臨床觀察。浙江中醫雜誌，42(10)，587。
  55. 席軍生,傅延齡(2006)。黃芩湯對胃腸道疾病的作用機理。光明中醫，21(10)，65-66。
  56. 高木村(1996).台灣民間藥 3.台北:南天書局出版社.
  57. 高尚志,陳幸一(2017)。抗血管新生藥物簡介。台灣醫界，60(8)，30-32。
  58. 張成晶,朱許麗,張穎慧,李杰(2018)。基於寒熱錯雜病機中醫藥在胃癌各階段防治中的研究。中國中醫基礎醫學雜誌，24(4)，510-512。
  59. 張威,越慶春,史國兵(2013)。黃耆桂枝五物湯治療神經痛的研究進展。中華中醫藥學刊，31(7)，1564-1566。
  60. 張素芳,王曉翠,陳喆(2007)。中醫藥對惡性腫瘤放療減毒作用的臨床研究現狀。中西醫結合學報，5(4)，470-473。
  61. 張敏妮(2012)。廣州中醫藥大學。
  62. 張景明,陳仁亮,鍾元強,張金堅(2015)。晚期大腸直腸癌的個人化醫療。台灣醫界，58(2)，19-23。
  63. 張藝嚴,高冰(2017)。中西醫結合治療肺癌臨床思路。亞太傳統醫藥，13(1)，51-52。
  64. 盛軍章,李慶亮,任志冰,冷啟寧(2015)。當歸四逆湯，補陽還五湯，黃耆桂枝五物湯治療奧沙利鉑所致周圍神經病變的臨床對比研究。中醫臨床研究，7(3)，18-20。
  65. 連頌平,林佳霓,王榮德(2018)。大腸癌篩檢陽性後，人生就變黑白？。台灣醫界，61(2)，28-29。
  66. 陳弘益(2015)。大腸癌各分期的藥物治療。藥學雜誌，31(4)，68-73。
  67. 陳宇鵬(2009)。加味當歸四逆湯預防治療奧沙利鉑所致神經毒性 35 例臨床觀察。臨床醫藥實踐，2(3)，1507-1508。
  68. 陳潮祖(2009).中醫治法與方劑.北京:人民衛生出版社.
  69. 彭仁通(2015)。當歸四逆湯合陽和湯防治奧沙利鉑所致神經毒性療效觀察。中醫臨床研究，7(12)，88-90。
  70. 黃金昶(2003)。經方在腫瘤併發症中的應用探要。中醫藥學刊，12，2126-2127。
  71. 黃金昶(2012).黃金昶中醫腫瘤辨治十講.北京:中國中醫藥出版社.
  72. 黃厚澤,潭明雄,李冬青(2011)。中藥白花丹藥理和臨床應用研究。衛生職業教育，29(5)，154-155。
  73. 黃敬倫(2008)。轉移性大腸直腸癌的治療。中華癌醫會誌，24(2)，199-202。
  74. 劉慧,周之毅,吳麗英,王文海,周榮耀,黃建平,鞏航軍,韓剛,湯雪峰,王以東(2011)。黃耆桂枝五物湯治療奧沙利鉑周圍神經毒性的臨床觀察。上海中醫藥雜誌，45(3)，44-47。
  75. 鄧海燕,賈立群,潘琳,于莉莉,李學,郭艷茹(2006)。生姜瀉心湯預防伊立替康所致遲發性腹瀉的實驗研究。中日友好醫院學報，20(6)，344-347。
  76. 戴虹,潘宇,王曉露(2006)。補陽還五湯加味治療草酸鉑化療後周圍神經毒性 42 例。實用中醫內科雜誌，20(5)，518-519。
  77. 戴躍龍,白慧穎,竇永起(2015)。黃芩湯PHY906 的研究進展。武警後勤學院學報，24(9)，754-757。
被引用次数
  1. 蔡嘉一,陳有昱(2021)。中醫治療化療相關的睡醒障礙病例報告。中醫藥研究論叢，24(2)，57-64。
  2. 蔡金川,游榮聖,林原禾(2022)。大腸直腸癌化療毒性與舌象特徵之關係：一觀察型研究。中醫藥研究論叢，25(3)，1-12。
print cancel